Shanghai Xihua Scientific Co. Ltd. was founded in the China Pilot (Shanghai) Free Trade Zone in February 2015. Xihua has become an international biomedical technology entity company, which matches the quality standards not only in China, but also in the United States.

Xihua Scientific has two locations in the Shanghai Zhang Jiang Pharm Valley. Currently, there are over 5,0000 sq/ft of laboratory and office space, more than 180 employees, 25 sets of LC-MS, and more than 120 pieces of other equipment. In Princeton, New Jersey, Xihua has a strategic partner with Primera, a CMC and bio-analytical services laboratory, which has been inspected by the US FDA many times. Primera has about 100 researchers. Xihua provides one-stop service in late phase drug research and development, including generic drug CMC, formulation development, bioanalytical, clinical trial services and statistics. Xihua also has services in study and quality related consultation and training.

Xihua has established wide partnerships with more than 100 clients, which consist of pharmaceuticals companies, hospital clinical units, clinical CROs, universities and research institutes, and others.

Xihua has passed the laboratory quality assessment by the Department of Health in China for the past three years in a row, and has also completed more than 200 BE and innovative drug clinical studies. Among them, 40 projects of these projects have passed CFDA on-site inspection.  

For the last two years, Xihua was appointed by the CFDA to organize Training Courses on Technique and Quality Management for Clinical PK Samples Analysis. More than 200 people from domestic pharmaceutical companies completed the training.

Xihua is willing to share the experiences implementing Chinese and Western professional industry standards to provide high-quality services, make a contribution to improving drug quality, and promote human health.

News center